Navigation Links
ChanTest hires Chris Mathes as Chief Commercial Officer
Date:8/17/2012

CLEVELAND, Aug. 17, 2012 /PRNewswire/ -- Today ChanTest announces the hiring of Chris Mathes, Ph.D., M.B.A. to lead its business into a new era. Mathes starts September 1st as Chief Commercial Officer (CCO) and will oversee all sales, marketing and customer relations activities at ChanTest. He will also contribute to the forward looking and strategic guidance of ChanTest as a global player in the CRO industry.

(Photo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"Chris is a real ion channel guy," said Dr. Arthur "Buzz" Brown, CEO, President & Founder of ChanTest. "As CCO, he brings a unique mix of science and business to our company in order to make ChanTest's interface to the world even better."

Dr. Mathes has a Ph.D. in Neuroscience from UCLA and an MBA from Rutgers University. He has published several ion channel papers in peer reviewed journals over the past two decades.  In the last 10 years, Mathes has been a pioneer in the development and implementation of automated patch clamp systems for ion channel safety testing and drug discovery. 

"I'm really excited about this opportunity at ChanTest," Mathes said. "ChanTest is already the market leading ion channel CRO. My goal is to further enhance the brand and to expand the business.  I want to make sure that every pharmaceutical or biotech lab in the world accesses the ion channel and scientific expertise available at ChanTest."

About ChanTest Corporation (www.chantest.com)

ChanTest translates the most advanced Ion Channel, GPCR and Transporter technologies to provide safer, more effective medicines. By combining electrophysiology, molecular biology and cell culture including cell lines, stem cells and native cells ChanTest has developed biomarkers, reagents and services that greatly enhance drug discovery. The Company has alliances in which its technologies are integrated with medicinal, combinatorial and computational chemistry, animal models and clinical trials to provide modular or complete services along the drug development pathway. Since its inception in 1998, ChanTest has tested compounds for more than 500 global pharmaceutical and biotechnology companies. ChanTest's library of  ion channel cell lines, validated human stem cell-derived cardiomyocytes and  predictive nonclinical cardiac risk assessment program are  the most comprehensive available today. Because of ChanTest's seminal role in cardiac safety and its uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

CONTACT: Kate Siver, +1-216-332-1665, info@chantest.com


'/>"/>
SOURCE ChanTest Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
2. Health Revenue Assurance Associates Hires Valerie Rinkle as Vice President of Revenue Integrity Informatics
3. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
4. NHD Hires Ron Cronin as Executive Director
5. Millstone Medical Outsourcing Hires New Vice President Quality
6. Zimmer Holdings Names Christopher Begley to Board of Directors
7. Doug Pepper appointed as Chief Financial Officer at Cardiac Science
8. ADVENTRX Announces Appointment Of Chief Medical Officer
9. Accelr8 Appoints Steve Reichling Chief Financial Officer
10. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
11. Qforma Chief Technologist Honored as One of PharmaVOICE Magazines "100 Most Inspiring People in the Life Sciences"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
(Date:5/24/2016)... May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... on advancing renal care, today announced that Jeffrey ... in the following schedule of investor conferences. Where applicable, ... at http://ir.nxstage.com/ .   ... Conference NY, NY           Friday, June 10, 2016 1:30 ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... campaign returns for a third time to shed lights on the variety of topics ... and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in ...
(Date:5/27/2016)... ... May 27, 2016 , ... In ... the many who are unaware of the plight of aphasia. In collaboration with ... the “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
Breaking Medicine News(10 mins):